Corrigendum to “MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells” [Cancer Letters 355 (2014) 148–158] (Cancer Letters (2014) 355(1) (148–158), (S0304383514005047), (10.1016/j.canlet.2014.09.005));MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 148-158

  Wan, Hai Ying ^a   Li, Qin Qin ^a   Zhang, Yan ^a   Tian, Wei ^a   Li, Ya Nan ^a   Liu, Min ^a   Li, Xin ^a   Tang, Hua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

AmotL1; Cervical cancer cells; EMT; MiR 124; Vasculogenic mimicry

Indexed keywords

ANGIOMOTIN LIKE PROTEIN 1; MICRORNA 124; TUMOR PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; AMOTL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; C33A CELL LINE; CANCER INHIBITION; CELL MIGRATION; CELL MOTILITY; CERVICAL CANCER CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; TUMOR INVASION; TUMOR VASCULARIZATION; VASCULOGENIC MIMICRY; BINDING SITE; CARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR MIMICRY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; UTERINE CERVIX TUMOR; VASCULARIZATION;

3' UNTRANSLATED REGIONS; BINDING SITES; CARCINOMA; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MEMBRANE PROTEINS; MICRORNAS; MOLECULAR MIMICRY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 84907977713     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.02.014     Document Type: Erratum

References (43)

1. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet 2004, 5:522-531.
2. Fang L., Deng Z., Shatseva T., Yang J., Peng C., Du W.W., et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011, 30:806-821.
3. Su Y., Li X., Ji W., Sun B., Xu C., Li Z., et al. Small molecule with big role: MicroRNAs in cancer metastatic microenvironments. Cancer Lett 2014, 344:147-156.
4. Sonntag K.C., Woo T.U., Krichevsky A.M. Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp. Neurol 2012, 235:427-435.
5. Liu K., Zhao H., Yao H., Lei S., Lei Z., Li T., et al. MicroRNA-124 regulates the proliferation of colorectal cancer cells by targeting iASPP. Biomed Res. Int 2013, 2013:867537.
6. Zhang J., Lu Y., Yue X., Li H., Luo X., Wang Y., et al. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS ONE 2013, 8:e70300.
7. Li A., Lin X., Tan X., Yin B., Han W., Zhao J., et al. Circadian gene Clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124. FEBS Lett 2013, 587:2455-2460.
8. Lv Z., Yang L. MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol. Med. Rep 2013, 8:345-349.
9. Han Z.B., Yang Z., Chi Y., Zhang L., Wang Y., Ji Y., et al. MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell. Physiol. Biochem 2013, 31:823-832.
10. Lang Q., Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem. Biophys. Res. Commun 2012, 426:247-252.
11. Shi X.B., Xue L., Ma A.H., Tepper C.G., Gandour-Edwards R., Kung H.J., et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013, 32:4130-4138.
12. Yamane K., Jinnin M., Etoh T., Kobayashi Y., Shimozono N., Fukushima S., et al. Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J. Mol. Med 2013, 91:69-81.
13. Xia J., Wu Z., Yu C., He W., Zheng H., He Y., et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J. Pathol 2012, 227:470-480.
14. An L., Liu Y., Wu A., Guan Y. microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS ONE 2013, 8:e69478.
15. Hunt S., Jones A.V., Hinsley E.E., Whawell S.A., Lambert D.W. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett 2011, 585:187-192.
16. Wang P., Chen L., Zhang J., Chen H., Fan J., Wang K., et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 2014, 33:514-524.
17. Liang Y.J., Wang Q.Y., Zhou C.X., Yin Q.Q., He M., Yu X.T., et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013, 34:713-722.
18. Zhang S., Zhang D., Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007, 254:157-164.
19. Mulder W.J., Griffioen A.W. Imaging of angiogenesis. Angiogenesis 2010, 13:71-74.
20. Shaik S., Nucera C., Inuzuka H., Gao D., Garnaas M., Frechette G., et al. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J. Exp. Med 2012, 209:1289-1307.
21. Bratt A., Birot O., Sinha I., Veitonmaki N., Aase K., Ernkvist M., et al. Angiomotin regulates endothelial cell-cell junctions and cell motility. J. Biol. Chem 2005, 280:34859-34869.
22. Detmar M. Tumor angiogenesis. J. Invest. Dermatol 2000, 5:20-23. Symposium proceedings/the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research.
23. Chen Y., Gorski D.H. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008, 111:1217-1226.
24. Gest C., Mirshahi P., Li H., Pritchard L.L., Joimel U., Blot E., et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett 2012, 317:207-217.
25. Weng C., Dong H., Chen G., Zhai Y., Bai R., Hu H., et al. miR-409-3p inhibits HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin. Cancer Lett 2012, 323:171-179.
26. Zhou Q., Gallagher R., Ufret-Vincenty R., Li X., Olson E.N., Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27-~-24 clusters. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8287-8292.
27. Zhang Y., Wang X., Xu B., Wang B., Wang Z., Liang Y., et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol. Rep 2013, 30:1976-1984.
28. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol 1999, 155:739-752.
29. Zheng Y., Vertuani S., Nystrom S., Audebert S., Meijer I., Tegnebratt T., et al. Angiomotin-like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis. Circ. Res 2009, 105:260-270.
30. Paramasivam M., Sarkeshik A., Yates J.R., Fernandes M.J., McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol. Biol. Cell 2011, 22:3725-3733.
31. Nishimura M., Kakizaki M., Ono Y., Morimoto K., Takeuchi M., Inoue Y., et al. JEAP, a novel component of tight junctions in exocrine cells. J. Biol. Chem 2002, 277:5583-5587.
32. Sugihara-Mizuno Y., Adachi M., Kobayashi Y., Hamazaki Y., Nishimura M., Imai T., et al. Molecular characterization of angiomotin/JEAP family proteins: interaction with MUPP1/Patj and their endogenous properties. Genes Cells 2007, 12:473-486.
33. Ernkvist M., Birot O., Sinha I., Veitonmaki N., Nystrom S., Aase K., et al. Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells. Biochim. Biophys. Acta 2008, 1783:429-437.
34. Nakajima Y., Nakamura Y., Shigeeda W., Tomoyasu M., Deguchi H., Tanita T., et al. The role of tumor necrosis factor-alpha and interferon-gamma in regulating angiomotin-like protein 1 expression in lung microvascular endothelial cells. Allergol. Int 2013, 62:309-322.
35. Wang C., An J., Zhang P., Xu C., Gao K., Wu D., et al. The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation. Biochem. J. 2012, 444:279-289.
36. Skouloudaki K., Walz G. YAP1 recruits c-Abl to protect angiomotin-like 1 from Nedd4-mediated degradation. PLoS ONE 2012, 7:e35735.
37. Li L., Luo J., Wang B., Wang D., Xie X., Yuan L., et al. Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol. Cancer 2013, 12:163.
38. Zhang H., Wang Q., Zhao Q., Di W. MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J. Ovarian Res 2013, 6:84.
39. Patrie K.M. Identification and characterization of a novel tight junction-associated family of proteins that interacts with a WW domain of MAGI-1. Biochim. Biophys. Acta 2005, 1745:131-144.
40. Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013, 27:2192-2206.
41. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
42. Kraljevic Pavelic S., Sedic M., Bosnjak H., Spaventi S., Pavelic K. Metastasis: new perspectives on an old problem. Mol. Cancer 2011, 10:22.
43. Tammali R., Reddy A.B., Srivastava S.K., Ramana K.V. Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 2011, 14:209-221.